Why Clovis Oncology Fell 7.1% in August
Shares of Clovis Oncology (NASDAQ: CLVS), a commercial-stage biotech focused on cancer, fell more than 7% in August, according to data from S&P Global Market Intelligence. The decline was owed to the company sharing good and bad news with investors during in its second-quarter report.
Here's a review of the headline numbers from the company's second quarter:
Financial updates aside, Clovis also had several other highlights to share with investors:
Source: Fool.com
Bristol-Myers Squibb Aktie
57,91 €
2,15 %
Bristol-Myers Squibb sticht hervor mit 22 Buy- und nur 3 Sell-Einschätzungen.
Ein positives, aber moderates Potenzial für Bristol-Myers Squibb mit einem Kursziel von 61 € im Vergleich zu 57.91 €.
